168 related articles for article (PubMed ID: 29019336)
1. Chemotherapy-Induced Febrile Neutropenia in Solid Tumours.
Rasmy A; Al Mashiakhi M; Ameen A
Gulf J Oncolog; 2017 Sep; 1(25):77-84. PubMed ID: 29019336
[TBL] [Abstract][Full Text] [Related]
2. Febrile Neutropenia in Patients with Solid Tumors Undergoing Intravenous Chemotherapy.
Moreira-Pinto J; Leão I; Palmela C; Branco F; Godinho J; Simões P; Leal-Costa L; Lopes F; Faria A; Casa-Nova M; Escária A; Costa F; Galvão I; Teixeira J; Passos-Coelho JL
Oncol Res Treat; 2020; 43(11):605-612. PubMed ID: 32818937
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine pattern of usage, rate of febrile neutropaenia and treatment related death in asian cancer patients in clinical practice.
Phua VC; Wong WQ; Tan PL; Bustam AZ; Saad M; Alip A; Wan Ishak WZ
Asian Pac J Cancer Prev; 2015; 16(4):1449-53. PubMed ID: 25743814
[TBL] [Abstract][Full Text] [Related]
4. Risk of treatment related death and febrile neutropaenia with first line palliative chemotherapy for de novo metastatic breast cancer in clinical practice in a middle resource country.
Phua CE; Tang WH; Yusof MM; Saad M; Alip A; See MH; Taib NA
Asian Pac J Cancer Prev; 2014; 15(23):10263-6. PubMed ID: 25556458
[TBL] [Abstract][Full Text] [Related]
5. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae infection causing septic shock in cancer patients with chemotherapy-induced febrile neutropenia.
Kim YJ; Jung SM; Kang J; Ryoo SM; Sohn CH; Seo DW; Lim KS; Huh JW; Kim SH; Kim WY
Intern Emerg Med; 2019 Apr; 14(3):433-440. PubMed ID: 30600529
[TBL] [Abstract][Full Text] [Related]
7. Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study.
Rapoport BL; Aapro M; Paesmans M; van Eeden R; Smit T; Krendyukov A; Klastersky J
BMC Cancer; 2018 Sep; 18(1):917. PubMed ID: 30249215
[TBL] [Abstract][Full Text] [Related]
8. Incidence and risk factors of bacterial and fungal infection during induction chemotherapy for high-risk neuroblastoma.
Whittle SB; Williamson KC; Russell HV
Pediatr Hematol Oncol; 2017 Aug; 34(5):331-342. PubMed ID: 29200325
[TBL] [Abstract][Full Text] [Related]
9. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
10. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
[TBL] [Abstract][Full Text] [Related]
11. Risk predictors for adverse outcome in pediatric febrile neutropenia: Single center experience from a low and middle-income country.
Prasad M; Chinnaswamy G; Arora B; Vora T; Hawaldar R; Banavali S
Indian J Cancer; 2014; 51(4):432-7. PubMed ID: 26842150
[TBL] [Abstract][Full Text] [Related]
12. Risk of treatment related death and febrile neutropaenia with taxane-based adjuvant chemotherapy for breast cancer in a middle income country outside a clinical trial setting.
Phua CE; Bustam AZ; Yusof MM; Saad M; Yip CH; Taib NA; Ng CH; Teh YC
Asian Pac J Cancer Prev; 2012; 13(9):4623-6. PubMed ID: 23167391
[TBL] [Abstract][Full Text] [Related]
13. A Patient Risk Model of Chemotherapy-Induced Febrile Neutropenia: Lessons Learned From the ANC Study Group.
Lyman GH; Poniewierski MS
J Natl Compr Canc Netw; 2017 Dec; 15(12):1543-1550. PubMed ID: 29223991
[TBL] [Abstract][Full Text] [Related]
14. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
Mądry R; Popławska L; Haslbauer F; Šafanda M; Ghizdavescu D; Benkovicova J; Csőszi T; Mihaylov G; Niepel D; Jaeger C; Frkanova I; Macovei A; Staudigl C
Wien Klin Wochenschr; 2016 Apr; 128(7-8):238-47. PubMed ID: 26745973
[TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy-induced febrile neutropenia: About 186 episodes. Clinical, microbiological and therapeutic characteristics].
Masmoudi S; Khanfir A; Maalej-Mezghan S; Hammami A; Frikha M
Tunis Med; 2015 Apr; 93(4):217-22. PubMed ID: 26375737
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for refractory febrile neutropenia in urological chemotherapy.
Yasufuku T; Shigemura K; Tanaka K; Arakawa S; Miyake H; Fujisawa M
J Infect Chemother; 2013 Apr; 19(2):211-6. PubMed ID: 23011233
[TBL] [Abstract][Full Text] [Related]
17. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia.
Choi CW; Sung HJ; Park KH; Yoon SY; Kim SJ; Oh SC; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
Am J Hematol; 2003 Aug; 73(4):263-6. PubMed ID: 12879430
[TBL] [Abstract][Full Text] [Related]
18. Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data.
Lalami Y; Klastersky J
Crit Rev Oncol Hematol; 2017 Dec; 120():163-179. PubMed ID: 29198330
[TBL] [Abstract][Full Text] [Related]
19. Incidence and Predictors of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy in Korea.
Kim HS; Lee SY; Kim JW; Choi YJ; Park IH; Lee KS; Seo JH; Shin SW; Kim YH; Kim JS; Park KH
Oncology; 2016; 91(5):274-282. PubMed ID: 27623006
[TBL] [Abstract][Full Text] [Related]
20. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours.
Aapro MS; Cameron DA; Pettengell R; Bohlius J; Crawford J; Ellis M; Kearney N; Lyman GH; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
Eur J Cancer; 2006 Oct; 42(15):2433-53. PubMed ID: 16750358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
